Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia

TY - JOUR

T1 - Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia

AU - Fijal, B. A.

AU - Kinon, B. J.

AU - Kapur, S.

AU - Stauffer, V. L.

AU - Conley, R. R.

AU - Jamal, H. H.

AU - Kane, J. M.

AU - Witte, M. M.

AU - Houston, J. P.

PY - 2009

Y1 - 2009

N2 - Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were treated with oral risperidone. All patients in the exploratory (78 African Americans) and validation (65 whites) data sets received risperidone 2-6 mg per day over 2-12 weeks. Two SNPs were found to have significant associations with response to risperidone over 2-12 weeks in both African-American and white patients and had a consistent direction of effect in both cohorts. Metabotropic glutamate receptor (GRM3) SNP, rs724226, was associated with a change in the positive and negative syndrome scale (PANSS) total response. Catechol-O-methyltransferase (COMT) SNP, rs165599, was moderately associated with a change in the PANSS Negative score. The greater prevalence of poor-responder GRM3 and COMT alleles in white versus African-American patients might have a clinical significance in evaluating the ethnic-specific response to risperidone. The Pharmacogenomics Journal (2009) 9, 311-318; doi:10.1038/tpj.2009.24; published online 19 May 2009

AB - Clinical trial data were evaluated for the association between 22 single-nucleotide polymorphisms (SNPs) and response in acutely ill patients diagnosed with schizophrenia, schizoaffective disorder or schizophreniform disorder, who were treated with oral risperidone. All patients in the exploratory (78 African Americans) and validation (65 whites) data sets received risperidone 2-6 mg per day over 2-12 weeks. Two SNPs were found to have significant associations with response to risperidone over 2-12 weeks in both African-American and white patients and had a consistent direction of effect in both cohorts. Metabotropic glutamate receptor (GRM3) SNP, rs724226, was associated with a change in the positive and negative syndrome scale (PANSS) total response. Catechol-O-methyltransferase (COMT) SNP, rs165599, was moderately associated with a change in the PANSS Negative score. The greater prevalence of poor-responder GRM3 and COMT alleles in white versus African-American patients might have a clinical significance in evaluating the ethnic-specific response to risperidone. The Pharmacogenomics Journal (2009) 9, 311-318; doi:10.1038/tpj.2009.24; published online 19 May 2009

U2 - 10.1038/tpj.2009.24

DO - 10.1038/tpj.2009.24

M3 - Article

SN - 1473-1150

VL - 9

SP - 311

EP - 318

JO - PHARMACOGENOMICS JOURNAL

JF - PHARMACOGENOMICS JOURNAL

IS - 5

ER -